Almatica is focused on the development, acquisition and commercialization of brand named pharmaceutical products. We have a current portfolio of US branded pharmaceutical products covering a wide range of therapeutic areas including: psychiatry, pain management, anti-infectives and cardiovascular related disorders. Almatica is actively pursuing the expansion of its US product portfolio through the development of its own product pipeline and through the in-licensing and acquisition of products that are either marketed or in late stage development. The growth of our business is supported by a broad range of in-house commercial, manufacturing and R&D related capabilities.

Almatica Pharma LLC is a US subsidiary of Alvogen. The parent company Alvogen, is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. The company has commercial operations in 20 countries with 1,700 employees and operates four manufacturing and development hubs in the U.S., Korea and Taiwan.

Alvogen Core Businesses include:

  • Almatica Pharma LLC focusing on branded pharmaceutical products
  • Alvogen Inc. focusing on generic pharmaceutical products for the United States, Europe, Asia and Latin America
  • Norwich Pharmaceuticals offering contract manufacturing to a diversified group of pharmaceutical companies
  • Norwich Clinical Services offering outsourced pharmacovigilance, biostudies, and clinical trial programs
  • Alvotech an independent sister company of Alvogen, focused on development and manufacturing of high quality biosimilar products.

For additional information, visit